Drugs used to treat autoimmune diseases typically produce systemic immune suppression, and ShK domain peptides can target the Kv1.3 channel to selectively inhibit CCR7-TEM lymphocytes and reduce this side effect [23]. Here, SHPK is linked to autoimmune disease.